 I've been taking care of multiple myeloma patients since 1990. When I used to give talks about multiple myeloma back then, the median survivals that we used to talk about were measured in months. Today, the median survival for multiple myeloma patients diagnosed a decade ago is about a decade. So for a multiple myeloma patient diagnosed today, it's certainly going to be better than that. One of the most recent breakthroughs in multiple myeloma, certainly the one that is getting the most press of late, is the first approval for cartesal therapies in multiple myeloma. It has turned around the lives of some of our patients. Some are here clearly because of cartesals and they wouldn't still be here otherwise. Cartesal therapy has been a miracle for some people. Stem cell transplants are one of the mainstays of treatment for multiple myeloma and despite the fact that we've been doing them for better part of two or three decades, they remain a mainstay of therapy and they remain the one option that we have that sometimes offer patients very extended remissions and really nothing else that we do in multiple myeloma comes close to stem cell transplantation in terms of offering that opportunity. The future for patients with multiple myeloma I think is bright. The future has new drugs. The future, perhaps more importantly than that, has a better understanding of the individual patient's disease. We tend to lump myeloma, make it sound like myeloma is one diagnosis. Myeloma is many diagnoses and we are going to evolve technologies that allow us to say, okay, you're a patient that fits into this category and patients who fit into this category shouldn't be treated like patients who fit into this category. I think that the directed therapies, the therapies that target very specific mutations, very specific alterations are going to be extremely exciting things. But on top of that we've talked about CAR T cells. T cells are just one of the immune cells that we have that are capable of killing cancer cells and so we're going to start leveraging some other types of immune cells as part of the treatment for cancer in general, but myeloma as well. And I think that this is all very exciting stuff.